Sfoglia per AUTORE
MERLI F
Collezione AO Cuneo

  

Items : 14

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25.

2023
ASL Torino 5
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara

Coviello E; Cilloni D; Passamonti F; Corradini P; Bertù L; Guidetti A; Visco C; Pagano L; Gherlinzoni F; Galimberti S; Tisi MC; Cudillo L; Gentile M; Mohamed S; Visani G; Federici AB; Della Porta MG; Mauro FR; Gambacorti-Passerini C; Massaia M; Bocchia M; Scattolin A; Billio A; Marchesi F; Trentin L; Cattaneo C; Derenzini E; Fracchiolla NS; Romano A; et alii...

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
AOU Alessandria

Ladetto M; Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Musto P; Coviello E; Romano A; Passamonti F; Corradini P; Krampera M; Tosi P; Lanza F; Candoni A; Selleri C; Conconi A; Visani G; Vallisa D; Venditti A; Gambacorti-Passerini C; Rigacci L; La Barbera EO; Corso A; Armiento D; Cilloni D; Cardinali V; Galimberti S; Bocchia M; et alii...

HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. in Journal of personalized medicine / J Pers Med. 2022 Feb 15;12(2):285. doi: 10.3390/jpm12020285.

2022
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

De Luca G; Peri V; Ferrero S; Cervi L; Ragaini S; Al Essa W; Battaglini M; Cavallo F; Grimaldi D; Botto B; Ghione P; Zilioli VR; Merli F; Dogliotti I; Clerico M; Marzano A;

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.

2022
AO Cuneo
ASL Torino 5
AOU Città della Salute di Torino

Passamonti F; Arcaini L; Bruno R; Antonio Grossi P; Corradini P; Pagano L; Busca A; Giuliani N; Luppi M; Tosi P; Mohamed S; Corso A; Rigacci L; Giovanni Della Porta M; Lanza F; Venditti A; Massimo Lemoli R; Billio A; Gentile M; Falini B; Turrini M; Tafuri A; Morotti A; Chiara Tisi M; Galimberti S; Coviello E; Trentin L; Cuneo A; Bocchia M; et alii...

Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. in Annals of hematology / Ann Hematol. 2021 Oct;100(10):2547-2556. doi: 10.1007/s00277-021-04604-x. Epub 2021 Jul 30.

2021
AO Cuneo

Ciammella P; Ghiggi C; Gallamini A; Sorasio R; Balzarotti M; Giordano L; Chimienti E; Rodari M; Liberati AM; Fabbri A; Ricci F; Bonfichi M; Kovalchuk S; Pulsoni A; Musso M; Palombi F; Consoli U; Carella M; Specchia G; Califano C; Spina M; Mazza R; Santoro A; Ricardi U; Chauvie S; Carlo-Stella C; Merli F;

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. in British journal of haematology / Br J Haematol. 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16.

2021
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Bertù L; Pagano L; Corradini P; Musto P; Petrucci L; Zaja F; Grossi PA; Visani G; Lanza F; Cattaneo C; Mina R; La Barbera EO; Cardinali V; Galimberti S; Luppi M; Armiento D; Candoni A; Krampera M; Fracchiolla N; Bocchia M; Marchesi F; Tafuri A; Pinto A; Arcaini L; Ladetto M; Massaia M; Busca A; Venditti A; Romano I; et alii...

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. in Oncotarget / Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

2017
AOU Città della Salute di Torino
AO Cuneo

Cuneo A; Cavo M; Vianelli N; Breccia M; Bacchi Reggiani ML; Merli F; Fanin R; Lemoli RM; Vitolo U; Di Raimondo F; Aversa F; Catani L; Sabattini E; Spinsanti M; De Matteis G; Anaclerico B; Cerqui E; de Marchi F; Scaffidi L; Di Veroli A; Latagliata R; Bosi C; Crugnola M; Ibatici A; Cavazzini F; Tieghi A; Bergamaschi M; Polverelli N; D'Adda M; et alii...

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. in The Lancet. Haematology / Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

2016
AO Cuneo
AOU Città della Salute di Torino

Pileri SA; d'Amore F; Zinzani PL; Gascoyne RD; Broccoli A; Argnani L; Steidl C; Subocz E; Rybka J; Tajer J; Kulikowski W; Zaucha JM; Hamilton-Dutoit S; Kamper P; Piccaluga PP; Borra A; Stelitano C; Trentin L; Patti C; Romano A; Levis A; Merli F; Vitolo U; Rigacci L; Biggi A; Sista MT; Fanti S; Fuligni F; Agati P; et alii...

Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. in Haematologica / Haematologica. 2016 Apr;101(4):e139-41. doi: 10.3324/haematol.2015.138388. Epub 2015 Dec 24.

2016
AO Cuneo

Salati M; Capodanno I; Chauvie S; Gandolfi L; Pesce EA; Merli F; Pellegrini C; Luminari S; Federico M; Argnani L; Zinzani PL;

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). in American journal of hematology / Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

2015
AO Cuneo
AOU Città della Salute di Torino

Bosi A; Gotti M; Rosaria S; Maria SP; Levis A; Stefoni V; Vitolo U; Spina M; Stelitano C; Balzarotti M; Castagnoli A; Merli F; Zinzani PL; Biggi A; Rigacci L; Puccini B; Gallamini A;

Lack of prognostic value for peripheral absolute monocyte count in a population of diffuse large b-cell lymphoma in the rituximab era in Hematological Oncology

2015
AO Cuneo
AOU Città della Salute di Torino

Aprile Von Hohenstaufen K; Gulden-Sala W; Margiotta-Casaluci G; Franceschetti S; Moccia AA; Bertoni F; Cavalli F; Stathis A; Ghielmini M; Stussi G; Zucca E; Gaidano G; Conconi A; Canepari M; Gonella A; Castellino C; Sorasio R; Bonferroni M; Mattei D; Mordini N; Borra A; Rapezzi D; Margaria F; Conte E; Celeghini I; Bertolotti L; Fiore F; Grasso M; Ciammella P; et alii...

A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report in Journal of Clinical Oncology

2014
AO Cuneo

Federico M; Pesce EA; Merli F; Luminari S; Chauvie S; Pellegrini C; Marcheselli L; Capodanno I; Ilariucci F; Salati M; Argnani L; Zinzani PL;

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2007 Aug 20;25(24):3746-52. doi: 10.1200/JCO.2007.11.6525. Epub 2007 Jul 23.

2007
AO Cuneo

Biggi A; Vitolo U; Stelitano C; D'Amore F; Di Raimondo F; Loft A; Patti C; Hansen M; Merli F; Specht L; Rigacci L; Hutchings M; Gallamini A; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A;

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. in Haematologica / Haematologica. 2006 Apr;91(4):475-81.

2006
AO Cuneo

Levis A; Torchio P; Gregianin M; Pelosi E; Versari A; Castagnoli A; Biggi A; Tavera S; Stelitano C; Trentin L; Iannitto E; Sancetta R; Vitolo U; Luminari S; Capodanno I; Bosi A; Nassi L; Merli F; Gallamini A; Rigacci L;